Gentherm Q2 Earnings Call Highlights
Gentherm (NASDAQ:THRM) reported adjusted EBITDA of $48.8M (11.7% of sales) and adjusted EPS of $0.75 for Q2. Management cited margin pressure from timing, inventory reductions and warranty accruals. Gentherm raised 2026 guidance to $1.6B revenue and $185M-$200M adjusted EBITDA, and expects ThermAffyx initial sales in Q3.
How this was made
The 30-second read
Why it matters
The key tradable update is the raised 2026 guidance with quantified margin and cash flow ranges, plus committed financing and a planned capital allocation framework tied to the Modine close. Additional disclosures on warranty accrual rationale and new medical and non-automotive customer traction inform near-term execution risk.
Market read
Raised 2026 targets and clarified cash flow and margin seasonality can drive re-rating, while Q3 margin softness and warranty accrual specifics keep near-term risk elevated.
What to watch
The article notes the 2026 guidance excludes Modine impact, so investors may still discount the deal’s ultimate synergy and timing until sign-to-close deliverables are fully completed.
Background
Gentherm’s Q2 call covered automotive performance, margin drivers, and expansion into medical and non-light-vehicle markets, alongside progress toward its Modine Performance Technologies combination.
Ticker impact
Gentherm raised 2026 revenue, adjusted EBITDA, and adjusted free cash flow guidance, while detailing margin headwinds and Q3-to-Q4 rebound expectations.
Bias toward upside repricing into the Modine close window, with near-term caution for Q3 margin softness.
The article provides specific updated 2026 targets (revenue $1.6B midpoint, adjusted EBITDA $185M-$200M, FCF $85M-$100M) and ties them to seasonality and balance-sheet capacity for the Modine transaction.
Market effects
Thermal management suppliers may see read-across demand confidence as Gentherm expands beyond light vehicles into home and office and medical commercialization.
China strength is highlighted via domestic OEM program launches, which can support regional demand expectations for automotive thermal components.
Modine combination framing suggests consolidation in thermal and precision flow management, potentially affecting competitive positioning across global vehicle and industrial end markets.
Counterpoint
The guidance raise still comes with explicit Q3 margin weakness and warranty accrual-driven noise, so near-term earnings quality may disappoint even if full-year targets hold.
Key entities
- companyGentherm
Raised 2026 guidance and discussed margin headwinds, warranty accrual drivers, expansion into home and office, and FDA 510(k) clearance for ThermAffyx.
- companyModine Performance Technologies
Planned combination; Gentherm expects early Q4 close and provided committed financing and post-close leverage expectations.
- companyInnovative Medical Equipment (IME)
Acquired July 1 for $34 million, projected to contribute about $17 million 2026 revenue with 20% EBITDA margins.
- productThermAffyx
Received FDA 510(k) clearance; company expects initial sales in Q3.
